Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute Leukemia | Zendy

Di Wu | Zendy; Wenlan Chen | Zendy; Zhichao Chen | Zendy; Qiubai Li | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute Leukemia

Author(s) -

Di Wu,

Wenlan Chen,

Zhichao Chen,

Qiubai Li

Publication year - 2021

Publication title -

case reports in hematology

Language(s) - English

Resource type - Journals

eISSN - 2090-6560

pISSN - 2090-6579

DOI - 10.1155/2021/6661109

Subject(s) - venetoclax , medicine , myeloid leukemia , hypomethylating agent , phenotype , regimen , malignancy , leukemia , oncology , myeloid , complete remission , cancer research , chemotherapy , gene , chronic lymphocytic leukemia , genetics , biology , gene expression , dna methylation

Mixed phenotype acute leukemia (MPAL) is a rare hematological malignancy that lacks consensus on optimal management. We report for the first time two cases of treatment-naïve B/myeloid MPAL patients treated with a novel chemo-free regimen using venetoclax combined with hypomethylating agents, which successfully induced complete remission with tolerable toxicities.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research